CLAIMS

1. A cheese comprising angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.02 to 1.6.

2. A method of preventing bone diseases comprising ingesting the cheese according to claim 1 in an amount of 20 g/day or more.

3. A method of producing the cheese according to claim 1, comprising mixing angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate with a raw material cheese and/or a cheese curd.

4. A method of producing the cheese according to claim 1, comprising mixing a raw material cheese with angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate, and emulsifying and cooling the mixture.

CLAIMS

1. A cheese comprising angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.02 to 1.6.

2. A method of preventing and/or treating at least one of bone diseases, fracture, rheumatism and arthritis comprising administering to a subject in need thereof the cheese according to claim 1 in an amount of 20 g/day or more.

3. A method according to claim 2 wherein the bone disease is osteoporosis.

4. A method of producing the cheese according to claim 1, comprising mixing angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate with a raw material cheese and/or a cheese curd.

5. A method of producing the cheese according to claim 1, comprising mixing a raw material cheese with angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate, and emulsifying and cooling the mixture.

6. Use of (i) angiogenin and/or angiogenin hydrolysate and (ii) cystatin and/or cystatin hydrolysate in the manufacture of a medicament for the prevention and/or treatment of at least one of bone disease, fracture, rheumatism and arthritis wherein the angiogenin and/or angiogenin hydrolysate is in an amount of 6.5mg/100g to 160 mg/100 g of the medicament and wherein the cystatin and/or cystatin hydrolysate is in the mass ratio of 0.02 to 1.6 to the angiogenin and/or angiogenin hydrolysate.

7. Use according to claim 6 wherein the bone disease is osteoporosis.

8. Use according to claim 6 or 7 wherein the medicament is for administration in an amount of 20 g/day or more.

9. Use according to any one of claims 6 to 8 wherein the medicament is a cheese.

o